Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
Type:
Grant
Filed:
July 3, 2019
Date of Patent:
October 4, 2022
Assignee:
H. Lundbeck A/S
Inventors:
André Faldt, Heidi Lopez de Diego, Rene Holm, Michael J. Mealy
Abstract: Methods are provided for the synthesis and secretion of recombinant hetero-multimeric proteins in mating competent yeast. A first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.
Type:
Grant
Filed:
March 11, 2019
Date of Patent:
September 20, 2022
Assignees:
KECK GRADUATE INSTITUTE, H. LUNDBECK A/S
Inventors:
James M. Cregg, John A. Latham, Mark Litton, Randall Schatzman, Ilya I. Tolstrorukov
Abstract: Methods for producing heterologous proteins are disclosed. In particular, the present disclosure provides improved methods of producing desired proteins, including multi-subunit proteins such as antibodies, with a higher yield and improved purity. In exemplary embodiments, the transformed cells are a yeast, e.g., methylotrophic yeast such as Pichia pastoris.
Type:
Grant
Filed:
October 24, 2018
Date of Patent:
September 20, 2022
Assignee:
H. LUNDBECK A/S
Inventors:
Gary Lesnicki, Patricia Dianne McNeill, Franz Hartner, Mark Young
Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
Type:
Application
Filed:
July 30, 2020
Publication date:
September 8, 2022
Applicant:
H. Lundbeck A/S
Inventors:
Anette Graven Sams, Mario Rottlãnder, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen, Jesper Frank Bastlund, Jelena Ivkovic, Karina Krøjer Søby, Morten Grupe Larsen
Abstract: Provided herein are substituted 1,1,1,3,3,3-hexafluoropropan-2-yl 6-azaspiro[2.5]octane-6-carboxylate compounds and pharmaceutical compositions comprising said compounds. The compounds and compositions provided herein are useful as inhibitors of MAGL. Furthermore, the compounds and compositions as provided herein are useful for the treatment of diseases and disorders benefiting from the inhibition of MAGL.
Type:
Grant
Filed:
November 11, 2021
Date of Patent:
September 6, 2022
Assignee:
H. LUNDBECK A/S
Inventors:
John J. M. Wiener, Cheryl A. Grice, Daniel J. Buzard, Justin S. Cisar, Olivia Delene Weber, Amy Allan, Nicholas Raffaele, Jeanne Moody, Michael B. Shaghafi
Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
Type:
Grant
Filed:
February 4, 2020
Date of Patent:
September 6, 2022
Assignee:
H. Lundbeck A/S
Inventors:
Mario Rottlander, Anette Graven Sams, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen
Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.
Type:
Grant
Filed:
February 3, 2020
Date of Patent:
August 30, 2022
Assignee:
H. LUNDBECK A/S
Inventors:
Andrew Lawrence Feldhaus, Leon Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katie Olson Anderson, Ethan Wayne Ojala, Pei Fan, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Jeffrey T. L. Smith, John Latham
Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
Type:
Grant
Filed:
August 27, 2020
Date of Patent:
August 23, 2022
Assignee:
H. Lundbeck A/S
Inventors:
Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward Van Den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
Abstract: The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
Type:
Application
Filed:
July 28, 2021
Publication date:
August 18, 2022
Applicant:
H. Lundbeck A/S
Inventors:
Klaus Gjervig Jensen, Lisbet Kværnø, Morten Jørgensen, Martin Juhl
Abstract: The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
Type:
Application
Filed:
May 19, 2020
Publication date:
July 14, 2022
Applicant:
H. Lundbeck A/S
Inventors:
Morten Jørgensen, Erhad Ascic, Martin Juhl, Klaus Gjervig Jensen, Ask Püschl, Benny Bang-Andersen
Abstract: The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
Type:
Application
Filed:
January 25, 2022
Publication date:
July 7, 2022
Applicant:
H. Lundbeck A/S
Inventors:
John Paul Kilburn, Erhad Ascic, Mauro Marigo, Laurent David
Abstract: The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
Type:
Application
Filed:
May 19, 2020
Publication date:
July 7, 2022
Applicant:
H. Lundbeck A/S
Inventors:
Morten Jørgensen, Martin Juhl, Klaus Gjervig Jensen
Abstract: The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
Type:
Application
Filed:
May 19, 2020
Publication date:
July 7, 2022
Applicant:
H. Lundbeck A/S
Inventors:
Morten Jørgensen, Martin Juhl, Klaus Gjervig Jensen, Lisbet Kvænø
Abstract: The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
Type:
Application
Filed:
May 19, 2020
Publication date:
July 7, 2022
Applicant:
H. Lundbeck A/S
Inventors:
Morten Jørgensen, Erhad Ascic, Karin Sjödin, Klaus Gjervig Jensen, Jarkko Tapani Rautio
Abstract: The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below and salts thereof The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease. The invention also relates to new intermediates of said process.
Type:
Application
Filed:
August 2, 2021
Publication date:
June 23, 2022
Applicant:
H. Lundbeck A/S
Inventors:
Martin Juhl, Frans Dennis Therkelsen, Tobias Gylling Frihed
Abstract: The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below and pharmaceutically acceptable salts thereof The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease. The invention also relates to a new intermediate of said process.
Type:
Application
Filed:
July 26, 2021
Publication date:
June 16, 2022
Applicant:
H. Lundbeck A/S
Inventors:
Martin Juhl, Lisbet Kværnø, Mikkel Fog Jacobsen
Abstract: The present invention relates to an in vitro assay for measuring phosphorylated tau in a sample, said assay comprises the use of 2 antibodies i) a capture antibody specific for pS396 on tau and ii) a detection antibody binding tau on a different epitope that the capture antibody.
Type:
Application
Filed:
March 24, 2020
Publication date:
June 16, 2022
Applicant:
H. Lundbeck A/S
Inventors:
Jan Torleif Pedersen, Thomas Karikari, Kina Höglund, Kaj Blennow, Mikkel Harndahl Harndahl, Henrik Zetterberg
Abstract: The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
Type:
Grant
Filed:
June 30, 2020
Date of Patent:
June 14, 2022
Assignee:
H. Lundbeck A/S
Inventors:
John Paul Kilburn, Erhad Ascic, Mauro Marigo, Laurent David
Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PH F) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
Type:
Application
Filed:
August 11, 2021
Publication date:
June 9, 2022
Applicant:
H. Lundbeck A/S
Inventors:
Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated.
Type:
Grant
Filed:
February 11, 2019
Date of Patent:
June 7, 2022
Assignee:
H. LUNDBECK A/S
Inventors:
Maria-Cristina Loomis, Leon Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren